165 episodes

Podcast by STAT

The Readout Loud STAT

    • Business
    • 4.7 • 224 Ratings

Podcast by STAT

    Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug

    Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug

    We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's such a big deal, and then we'll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we'll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.

    • 40 min
    Episode 163: Marilynn Marchione on covering the CRISPR babies scandal

    Episode 163: Marilynn Marchione on covering the CRISPR babies scandal

    First, we discuss why it's so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington correspondent Nicholas Florko joins us for a dive into the thousands of emails from Anthony Fauci made public this week, complete with a top-five countdown of messages both impactful and absurd. Finally, longtime Associated Press medical reporter Marilynn Marchione retired last week, and she calls in to talk about the biggest stories of her career.

    • 28 min
    Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA

    Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA

    STAT's Andrew Joseph joins us to talk about the two-year anniversary of the approval of gene therapy Zolgensma and the effect it has had on families dealing with the rare disease spinal muscular atrophy. Then, former FDA Commissioner Scott Gottlieb calls in with tips on Memorial Day grilling, notes on a recent Twitter spat, and thoughts on the origins of SARS-CoV-2.

    • 32 min
    Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity

    Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity

    First, we discuss Ginkgo Bioworks, the multibillion-dollar biotech company with grand ambitions, a famous ticker symbol, and an affinity for memes. Then, STAT’s Helen Branswell joins us to discuss a topic on everyone’s mind: How will the Covid-19 pandemic end? Finally, we’ll talk about the modern phenomenon of the pandemic celebrity and the case of Ashish Jha, TV’s ever-present Covid-19 expert.

    • 38 min
    Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit

    Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit

    Can we prevent the next Covid-19? Has the CDC become too cautious? And how many sensors should be worn to bed? First, our colleague Helen Branswell joins us to discuss where the world went wrong with Covid-19 and how to prepare for the next pandemic. Next, STAT D.C. correspondent Nicholas Florko calls in to talk about the public health experts who believe the Centers for Disease Control and Prevention has been too sluggish and conservative in recent months. Finally, our colleague Nick St. Fleur joins to recap this week’s STAT Health Tech Summit, which featured some boisterous CEOs, ambitious startups, and promising technologies.

    • 29 min
    Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging

    Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging

    First, Moderna and Pfizer are poised to make billions of dollars from their Covid-19 vaccines this year, and we discuss what that massive infusion of cash portends for both companies. Next, Thomas Bollyky of the Council on Foreign Relations joins us to explain what the U.S.'s support for waiving Covid-19 vaccine patents means — and doesn’t mean — for the global vaccination effort. Finally, STAT’s Megan Molteni calls in to share the story of a little-known biotech company recruiting patients to Mexico with the promise of an anti-aging gene therapy in an unregulated clinical trial.

    • 33 min

Customer Reviews

4.7 out of 5
224 Ratings

224 Ratings

Long time in China ,

Excellent

Highly quality podcast

liviayyyyy ,

Best biotech podcast ever

Love love this podcast! Wanted to to find something similar for a long time! I am glad I was able to find this podcast. The hosts are so knowledgeable and articulate.
Good flow, interesting story, and wonderful people! I just want more! Maybe twice a week?

Arlie K ,

Engaging & Informative!

A timely and informative listen on the lastest in biotechnology - no matter the subject, you’re guaranteed to gain something from every episode. Can’t recommend The Readout Loud enough! 🙌

Top Podcasts In Business

Listeners Also Subscribed To